Randomized Clinical Trials in Children - Ethical and Methodological Issues

Abstract

Randomization is an internationally accepted methodological tool used to perform sound clinical research. To ensure the clinical value of medical interventions, both evidence based medicine and new drug approvals require that randomized controlled trials (RCT) be conducted. Randomization prevents the manipulation of participant allocation and balances unknown confounders in a way no other method can. The gold standard RCT, however, is complex to conduct and requires significant financial and structural resources. In consequence, drug development and registration are primarily driven by the pharmaceutical industry. Within the field of pediatrics, we need high quality research tailored to children in order to reduce off-label use and to ensure that we expose children only to effective and, above all, safe drug treatments. The American and European regulatory authorities now offer programs to support such studies and clinical researchers and pharmaceutical industries are obliged to put them into practice in the best interest of the children. Issues relating to feasibility as well as ethical issues must be born in mind when planning RCTs in child populations. Obtaining informed assent from children in an adequate manner is one of several key elements. Moreover, it is essential to ensure equipoise before conducting a trial. Thus, issues relating to acceptability can be addressed and the discrimination of treatment groups within RCTs can be prevented. This narrative review addresses ethical and methodological aspects of RCTs in adults and especially in children and includes a quantitative analysis, which explores issues relating to the publication of RCTs.

Guidance in Social and Ethical Issues Related to Clinical, Diagnostic Care and Novel Therapies for Hereditary Neuromuscular Rare Diseases: “Translating“ the Translational

“…Furthermore, trials can produce large amounts of data, which takes time to collate and analyse. The challenge of analysis can also be complicated by the fact that many participants in RD trials are children affected with chronic diseases, which increases the complexity of interpreting the outcome 21 22 .…”

Ethical challenges in paediatric clinical trials in multiple sclerosis

“…There are strict ethical principles established for medical research involving human subjects. The internationally accepted requirements have been constituted in the Nuremberg Code of 1947, the Declaration of Helsinki [World Medical Association, 2008] [Henschel et al 2010].…”

Pediatric oncology for the general pediatrician

“…Technological and scientific breakthroughs will surely be needed to yield radically new treatment modalities for those tumor types that fail to respond to current approaches. Clinical development of any such novel agents or modalities will require the use of creative and innovative trial designs that will allow efficient detection of meaningful differences between low numbers of treated patients, which will be, more than before, geographically dispersed and molecularly heterogeneous [3].…”